ATE449850T1 - Mutanten von flt3-l und ihre verwendungen - Google Patents

Mutanten von flt3-l und ihre verwendungen

Info

Publication number
ATE449850T1
ATE449850T1 AT99930657T AT99930657T ATE449850T1 AT E449850 T1 ATE449850 T1 AT E449850T1 AT 99930657 T AT99930657 T AT 99930657T AT 99930657 T AT99930657 T AT 99930657T AT E449850 T1 ATE449850 T1 AT E449850T1
Authority
AT
Austria
Prior art keywords
flt3
mutant polypeptides
disclosed
nucleic acids
ligand
Prior art date
Application number
AT99930657T
Other languages
English (en)
Inventor
Thomas Graddis
Jeffrey Mcgrew
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Application granted granted Critical
Publication of ATE449850T1 publication Critical patent/ATE449850T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99930657T 1998-07-02 1999-06-25 Mutanten von flt3-l und ihre verwendungen ATE449850T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/109,100 US6291661B1 (en) 1998-07-02 1998-07-02 flt3-L mutants and method of use
PCT/US1999/014296 WO2000001823A2 (en) 1998-07-02 1999-06-25 Flt3-l mutants and methods of use

Publications (1)

Publication Number Publication Date
ATE449850T1 true ATE449850T1 (de) 2009-12-15

Family

ID=22325768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99930657T ATE449850T1 (de) 1998-07-02 1999-06-25 Mutanten von flt3-l und ihre verwendungen

Country Status (8)

Country Link
US (2) US6291661B1 (de)
EP (1) EP1092030B1 (de)
AT (1) ATE449850T1 (de)
AU (1) AU767149B2 (de)
CA (1) CA2332345A1 (de)
DE (1) DE69941701D1 (de)
NZ (1) NZ509576A (de)
WO (1) WO2000001823A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
EP1276501B9 (de) * 2000-04-25 2007-01-24 Immunex Corporation Behandlung von tumoren mit photodynamischer therapie
AU2002232447A1 (en) * 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
KR100951409B1 (ko) * 2001-01-09 2010-04-07 베일러 리서치 인스티튜트 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트
US20030017529A1 (en) * 2001-06-27 2003-01-23 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
WO2003032728A2 (en) * 2001-10-19 2003-04-24 Creighton University Methods for preventing or reversing asthma and compositions useful therefor
DE10158680B4 (de) * 2001-11-30 2004-04-08 Universitätsklinikum Hamburg-Eppendorf Verfahren zur ex vivo-Expansion und -Differenzierung von multipotenten Stammzellen
PL377028A1 (pl) * 2002-03-26 2006-01-23 Immunex Corporation Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
US7595154B2 (en) * 2002-06-13 2009-09-29 Oregon Health And Science University Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
EP1670492A4 (de) * 2003-09-29 2009-07-08 Warren Pharmaceuticals Inc Gewebeschützende zytokine zur behandlung und prävention von sepsis und bildung von adhäsionen
DE102004019323A1 (de) * 2004-04-21 2005-11-10 Toximed Gmbh Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen
US20080194474A1 (en) * 2004-05-14 2008-08-14 University Of Louisville Research Foundation, Inc. Methods for the Treatment of Autoimmune Diseases
CN1993460A (zh) * 2004-07-12 2007-07-04 索林集团意大利有限公司 用于培养人细胞的装置和方法
EP2338524B1 (de) * 2004-08-12 2013-05-22 Cedars-Sinai Medical Center Kombinierte Gentherapie zur Behandlung makroskopischer Glioma
US20070048254A1 (en) * 2005-08-24 2007-03-01 Mirus Bio Corporation Generation of dendritic cells
US8883493B2 (en) * 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2607477B1 (de) * 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US11246908B2 (en) 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
US20190328785A1 (en) * 2018-04-30 2019-10-31 The Board Of Regents Of The University Of Oklahoma Flt3-binding chimeric antigen receptors, cells, and uses thereof
JP2022529892A (ja) * 2019-03-28 2022-06-27 オリオニス バイオサイエンシズ，インコーポレイテッド Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体
WO2020198659A1 (en) * 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
CA3142513A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
CZ307995A3 (en) 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
NZ321039A (en) 1995-10-04 2001-03-30 Immunex Corp Use of flt3-ligand to augment immunizing effects of known cytokines by stimulating myeloid precursor cells, monocytic cells, macrophages, B-cells and dendritic cells from CD34+ bone marrow progenitors
US5885962A (en) 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand

Also Published As

Publication number Publication date
US7067118B2 (en) 2006-06-27
EP1092030B1 (de) 2009-11-25
US6291661B1 (en) 2001-09-18
DE69941701D1 (de) 2010-01-07
AU4714899A (en) 2000-01-24
US20020111475A1 (en) 2002-08-15
WO2000001823A2 (en) 2000-01-13
CA2332345A1 (en) 2000-01-13
AU767149B2 (en) 2003-10-30
NZ509576A (en) 2003-12-19
WO2000001823A3 (en) 2000-08-03
EP1092030A2 (de) 2001-04-18

Similar Documents

Publication Publication Date Title
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
CA2232727A1 (en) Novel variants of green fluorescent protein, gfp
NZ527182A (en) Neisseria meningitidis antigens and compositions
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
IL115792A0 (en) Al-1 neurothophic factor
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
DE3676683D1 (de) Mischung von derivaten von aminosaeuren, verfahren zur herstellung der mischung und verwendung der mischung zur mengenbestimmung der aminosaeuren.
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DE59005821D1 (de) Verfahren zur Herstellung von L-Isoleucin und dafür geeignete Mikroorganismen und rekombinante DNA.
SE9602822D0 (sv) New receptor
EP0816504A3 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
DE69934017D1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
DE59606567D1 (de) Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren
EP1331265A3 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
ATE332974T1 (de) Il-1/tnf-alpha-activated kinase (itak), und verfahren zu ihrer herstellung und verwendung
EP1026237A3 (de) Proteinkinase von Ton und Neurofilament PK40 und PK36
ATE103979T1 (de) Menschliches lymphotoxin.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties